BR112021017703A2 - - Google Patents

Info

Publication number
BR112021017703A2
BR112021017703A2 BR112021017703A BR112021017703A BR112021017703A2 BR 112021017703 A2 BR112021017703 A2 BR 112021017703A2 BR 112021017703 A BR112021017703 A BR 112021017703A BR 112021017703 A BR112021017703 A BR 112021017703A BR 112021017703 A2 BR112021017703 A2 BR 112021017703A2
Authority
BR
Brazil
Application number
BR112021017703A
Other languages
Portuguese (pt)
Other versions
BR112021017703A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112021017703A2 publication Critical patent/BR112021017703A2/pt
Publication of BR112021017703A8 publication Critical patent/BR112021017703A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112021017703A 2019-03-11 2020-03-10 Receptores de células t wt1 de alta avidez e usos dos mesmos BR112021017703A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816746P 2019-03-11 2019-03-11
PCT/US2020/021916 WO2020185796A1 (en) 2019-03-11 2020-03-10 High avidity wt1 t cell receptors and uses thereof

Publications (2)

Publication Number Publication Date
BR112021017703A2 true BR112021017703A2 (enrdf_load_html_response) 2021-11-16
BR112021017703A8 BR112021017703A8 (pt) 2023-04-18

Family

ID=70155376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017703A BR112021017703A8 (pt) 2019-03-11 2020-03-10 Receptores de células t wt1 de alta avidez e usos dos mesmos

Country Status (13)

Country Link
US (1) US12448430B2 (enrdf_load_html_response)
EP (1) EP3938386A1 (enrdf_load_html_response)
JP (1) JP7611844B2 (enrdf_load_html_response)
KR (1) KR20210138043A (enrdf_load_html_response)
CN (1) CN113784978B (enrdf_load_html_response)
AU (1) AU2020237043A1 (enrdf_load_html_response)
BR (1) BR112021017703A8 (enrdf_load_html_response)
CA (1) CA3132845A1 (enrdf_load_html_response)
EA (1) EA202192252A1 (enrdf_load_html_response)
IL (1) IL286202A (enrdf_load_html_response)
MX (1) MX2021010837A (enrdf_load_html_response)
SG (1) SG11202109745PA (enrdf_load_html_response)
WO (1) WO2020185796A1 (enrdf_load_html_response)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3551221T3 (pl) 2016-12-08 2022-02-28 Immatics Biotechnologies Gmbh Nowe receptory komórek t i immunoterapia z ich zastosowaniem
AU2021411495A1 (en) * 2020-12-31 2023-06-29 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
EP4608875A1 (en) * 2022-10-28 2025-09-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-wt1/hla antibodies and uses thereof
WO2025029648A1 (en) * 2023-07-28 2025-02-06 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting loxhd1-associated disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
KR100767554B1 (ko) 1998-07-31 2007-10-17 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
ES2292994T3 (es) 2002-03-15 2008-03-16 Cellectis Meganucleasas hibridas y de cadena sencilla y su utilizacion.
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
EP1850860A2 (en) 2005-01-13 2007-11-07 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
ATE549401T1 (de) 2005-10-18 2012-03-15 Prec Biosciences Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
KR101953237B1 (ko) 2010-05-17 2019-02-28 상가모 테라퓨틱스, 인코포레이티드 신규 dna 결합 단백질 및 이의 용도
CA2845536A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
BR112014029441B1 (pt) 2012-05-25 2022-10-18 Emmanuelle Charpentier Método de modificação de um dna alvo, composição, rna tendo como alvo dna, um ou mais ácidos nucleicos, kit, método para modular a transcrição específica do sítio em um dna alvo e método para modificar um polipeptídeo associado com um dna alvo
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3702463B1 (en) 2012-12-12 2025-03-19 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US9574000B2 (en) 2012-12-19 2017-02-21 Medimmune, Llc Anti-human B7-H4 antibodies and their uses
WO2015071474A2 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
SG10201804335QA (en) 2013-11-22 2018-06-28 Univ Illinois Engineered high-affinity human t cell receptors
CA2956545A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
CN107250159A (zh) 2014-10-03 2017-10-13 达纳－法伯癌症研究所公司 糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其使用方法
PT3653221T (pt) 2015-02-19 2022-11-08 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
WO2016141357A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
US11026969B2 (en) 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
CN108884167A (zh) 2016-03-15 2018-11-23 癌症研究技术有限公司 嵌合抗原受体
AU2017331362B2 (en) 2016-09-23 2025-01-23 Fred Hutchinson Cancer Center TCRs specific for minor histocompatibility (H) antigen HA-1 and uses thereof
ES3027565T3 (en) * 2017-04-24 2025-06-16 Ospedale San Raffaele Srl Tcr and peptides
LT3765615T (lt) 2018-03-14 2023-10-10 Arbor Biotechnologies, Inc. Nauji tiksliniai crispr dnr fermentai ir sistemos

Also Published As

Publication number Publication date
US12448430B2 (en) 2025-10-21
JP7611844B2 (ja) 2025-01-10
EA202192252A1 (ru) 2021-12-21
CA3132845A1 (en) 2020-09-17
WO2020185796A9 (en) 2020-10-15
BR112021017703A8 (pt) 2023-04-18
US20220160764A1 (en) 2022-05-26
AU2020237043A1 (en) 2021-09-30
WO2020185796A1 (en) 2020-09-17
JP2022525099A (ja) 2022-05-11
EP3938386A1 (en) 2022-01-19
CN113784978A (zh) 2021-12-10
IL286202A (en) 2021-10-31
KR20210138043A (ko) 2021-11-18
MX2021010837A (es) 2021-10-14
SG11202109745PA (en) 2021-10-28
CN113784978B (zh) 2025-07-25

Similar Documents

Publication Publication Date Title
BR112021017339A2 (enrdf_load_html_response)
BR112021018450A2 (enrdf_load_html_response)
BR112021017637A2 (enrdf_load_html_response)
BR112021017892A2 (enrdf_load_html_response)
BR112021017939A2 (enrdf_load_html_response)
BR112021017782A2 (enrdf_load_html_response)
BR112021017738A2 (enrdf_load_html_response)
BR112021016821A2 (enrdf_load_html_response)
BR112021018452A2 (enrdf_load_html_response)
BR112021017728A2 (enrdf_load_html_response)
BR112021016996A2 (enrdf_load_html_response)
BR112021018250A2 (enrdf_load_html_response)
BR112021017234A2 (enrdf_load_html_response)
BR112021018168A2 (enrdf_load_html_response)
BR112021017703A2 (enrdf_load_html_response)
BR112021017083A2 (enrdf_load_html_response)
BR112021013944A2 (enrdf_load_html_response)
BR112021017732A2 (enrdf_load_html_response)
BR112021015080A2 (enrdf_load_html_response)
BR112021017355A2 (enrdf_load_html_response)
BR112021018093A2 (enrdf_load_html_response)
BR112021018102A2 (enrdf_load_html_response)
BR112021017173A2 (enrdf_load_html_response)
BR112021018584A2 (enrdf_load_html_response)
BR112021017310A2 (enrdf_load_html_response)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FRED HUTCHINSON CANCER CENTER (US)